Boardroom Alpha
8-K primary document
LIMN · Current Report (Form 8-K) · Filed July 6, 2026

Liminatus Pharma Inc8-K exhibit

tm2619730d1_ex3-2.htm

 

Exhibit 3.2

 

CERTIFICATE OF MERGER

 

OF

 

InnocsAI LLC,

a Delaware limited liability company

 

WITH AND INTO

 

InnocsAI Merger Sub, Inc.,

a Delaware corporation

 

July 2, 2026

 

Pursuant to Title 6, Section 18-209 of the Delaware Limited Liability Company Act (“DLLCA”) and Title 8, Section 264 of the Delaware General Corporation Law (“DGCL”), the undersigned hereby certifies relating to the merger (the “Merger”) of InnocsAI LLC, a Delaware limited liability company (the “Disappearing Company”), with and into InnocsAI Merger Sub, Inc., a Delaware corporation (the “Surviving Company,” and together with the Disappearing Company, collectively, the “Constituent Entities”).

 

FIRST: The names and states of formation or incorporation, as applicable, of the Constituent Entities are:

 

Name State of Incorporation Type of Entity
     
InnocsAI LLC Delaware Limited Liability Company
     
InnocsAI Merger Sub, Inc. Delaware Corporation

 

SECOND: That certain Amended and Restated Merger Agreement, dated as of June 29, 2026 (as amended, the “Merger Agreement”), by and among the Constituent Entities and NamChul Jung, an individual and representative of the members of the Disappearing Company, has been approved, adopted, certified, executed and acknowledged by each of the Constituent Entities in accordance with Section 264 of the DGCL and Section 18-209 of the DLLCA, as applicable.

 

THIRD: The name of the surviving limited liability company is: InnocsAI Merger Sub, Inc.

 

FOURTH: The Certificate of Incorporation of the Surviving Company, as in effect immediately prior to the Merger, shall be the Certificate of Incorporation of the Surviving Company.

 

FIFTH: The Merger shall become effective upon filing of this Certificate of Merger with the Secretary of State of the State of Delaware.

 

 

 

SIXTH: An executed copy of the Merger Agreement is on file at the office of the Surviving Company at:

 

InnocsAI Merger Sub, Inc.

c/o Liminatus Pharma, Inc.
2251 Stern Goodman Street, Suite E

Fullerton, California 92833

 

SEVENTH: A copy of the Merger Agreement will be furnished by the Surviving Company, on request and without cost, to any stockholder of the Surviving Company and any member of the Disappearing Company.

 

* * * * *

 

 

 

IN WITNESS WHEREOF, the Surviving Company has caused this Certificate of Merger to be signed by an authorized person as of the date first written above.

 

  INNOCSAI MERGER SUB, INC.,
  a Delaware corporation
   
  By: /s/ Chris Kim
  Name: Chris Kim
  Title: CEO

 

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer